PDF(Pubmed)
Abstract：
There is a myriad of diseases that plague the world ranging from infectious, cancer and other chronic diseases with varying interventions. However, the dynamism of causative agents of infectious diseases and incessant mutations accompanying other forms of chronic diseases like cancer, have worsened the treatment outcomes. These factors often lead to treatment failure via different drug resistance mechanisms. More so, the cost of developing newer drugs is huge. This underscores the need for a paradigm shift in the drug delivery approach in order to achieve desired treatment outcomes. There is intensified research in nanomedicine, which has shown promises in improving the therapeutic outcome of drugs at preclinical stages with increased efficacy and reduced toxicity. Regardless of the huge benefits of nanotechnology in drug delivery, challenges such as regulatory approval, scalability, cost implication and potential toxicity must be addressed via streamlining of regulatory hurdles and increased research funding. In conclusion, the idea of nanotechnology in drug delivery holds immense promise for optimizing therapeutic outcomes. This work presents opportunities to revolutionize treatment strategies, providing expert opinions on translating the huge amount of research in nanomedicine into clinical benefits for patients with resistant infections and cancer.
摘要：
有无数的疾病困扰着世界，从传染性，癌症和其他慢性病，有不同的干预措施。然而,传染病病原体的动力和伴随其他形式的慢性疾病如癌症的不断突变，恶化了治疗结果。这些因素通常通过不同的耐药机制导致治疗失败。更多，开发新药的成本是巨大的。这强调了药物递送方法中的范式转变以实现期望的治疗结果的需要。纳米医学的研究越来越深入，已显示出有望改善临床前阶段药物的治疗效果，并增加疗效和降低毒性。不管纳米技术在药物输送中的巨大好处，监管批准等挑战，可扩展性，必须通过简化监管障碍和增加研究资金来解决成本影响和潜在毒性。总之,纳米技术在药物输送中的理念为优化治疗结果带来了巨大的希望。这项工作提供了彻底改变治疗策略的机会，提供专家意见，将纳米医学的大量研究转化为耐药感染和癌症患者的临床益处。
